肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 共识声明：前列腺癌质子治疗

2021-04-12 国外肿瘤科相关专家小组（统称） Int J Part Ther

前列腺癌

质子治疗在前列腺癌的治疗中是一种有前途也有争议的治疗方法。粒子治疗联合组(PTCOG)针对前列腺癌质子治疗的适应证、优点、缺点以及成本效益进行讨论，形成共识报告。

中文标题：

2021 共识声明：前列腺癌质子治疗

英文标题：

Consensus Statement on Proton Therapy for Prostate Cancer

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2021-04-12

简要介绍：

质子治疗在前列腺癌的治疗中是一种有前途也有争议的治疗方法。粒子治疗联合组(PTCOG)针对前列腺癌质子治疗的适应证、优点、缺点以及成本效益进行讨论，形成共识报告。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 共识声明：前列腺癌质子治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b31ea1c0022a998a, title=2021 共识声明：前列腺癌质子治疗, enTitle=Consensus Statement on Proton Therapy for Prostate Cancer, guiderFrom=Int J Part Ther, authorId=0, author=, summary=质子治疗在前列腺癌的治疗中是一种有前途也有争议的治疗方法。粒子治疗联合组(PTCOG)针对前列腺癌质子治疗的适应证、优点、缺点以及成本效益进行讨论，形成共识报告。, cover=https://img.medsci.cn/2021112/1635819287753_5579292.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Mon Apr 12 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">质子治疗在前列腺癌的治疗中是一种有前途也有争议的治疗方法。粒子治疗联合组(PTCOG)针对前列腺癌质子治疗的适应证、优点、缺点以及成本效益进行讨论，形成共识报告。</span></p>, tagList=[TagDto(tagId=781, tagName=前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=781, guiderKeyword=前列腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2071, appHits=104, showAppHits=0, pcHits=293, showPcHits=1967, likes=0, shares=4, comments=3, approvalStatus=1, publishedTime=Tue Nov 02 10:25:19 CST 2021, publishedTimeString=2021-04-12, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Nov 02 10:19:22 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Wed Jan 03 03:59:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 共识声明：前列腺癌质子治疗.pdf)])
2021 共识声明：前列腺癌质子治疗.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082020, encodeId=e48b1082020a8, content=对临床有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f231885199, createdName=ms1480598562844655, createdTime=Mon Dec 20 10:09:45 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069828, encodeId=9316106982838, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e45594142, createdName=ms3000001811637514, createdTime=Sat Nov 13 09:55:10 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069314, encodeId=ff8b1069314af, content=., beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7a5706011, createdName=ms6000002054994908, createdTime=Thu Nov 11 17:10:22 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-12-20 ms1480598562844655

    对临床有指导意义

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082020, encodeId=e48b1082020a8, content=对临床有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f231885199, createdName=ms1480598562844655, createdTime=Mon Dec 20 10:09:45 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069828, encodeId=9316106982838, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e45594142, createdName=ms3000001811637514, createdTime=Sat Nov 13 09:55:10 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069314, encodeId=ff8b1069314af, content=., beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7a5706011, createdName=ms6000002054994908, createdTime=Thu Nov 11 17:10:22 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-11-13 ms3000001811637514

    不错不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082020, encodeId=e48b1082020a8, content=对临床有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f231885199, createdName=ms1480598562844655, createdTime=Mon Dec 20 10:09:45 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069828, encodeId=9316106982838, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e45594142, createdName=ms3000001811637514, createdTime=Sat Nov 13 09:55:10 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069314, encodeId=ff8b1069314af, content=., beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7a5706011, createdName=ms6000002054994908, createdTime=Thu Nov 11 17:10:22 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-11-11 ms6000002054994908

    .

    0

相关指南

德国介入放射学会 (DeGIR) 关于前列腺动脉栓塞的立场文件

德国介入放射学会 (DeGIR) · 2020-11-05

2021NICE指南：阿帕鲁胺联合雄激素剥夺疗法治疗激素敏感性转移性前列腺癌

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-10-28

FDA指导原则：非转移性去势抵抗性前列腺癌：临床试验中无转移生存终点的考虑

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2021-10-01

前列腺癌睾酮管理中国专家共识(2021版)

中华医学会泌尿外科学分会(CUA) · 2021-04-30

2019 HKUA_HKSUO共识声明：晚期前列腺癌的管理

香港泌尿外科协会(HKUA,Hong Kong Urological Association) · 2021-04-17

2021 CUA/CUOG指南：去势抵抗性前列腺癌的管理

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2021-02-15

拓展阅读

2010 ACS 前列腺癌早期筛查指南

美国癌症学会(ACS,American Cancer Society) · 2010-03-01

2010CCO 前列腺癌根治性前列腺切除术病理T3或边缘阳性的辅助放射治疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-04-15

ESMO临床实践指南：前列腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

2008 前列腺癌骨转移临床诊疗专家共识（2008版）

恶性肿瘤骨转移及骨相关疾病临床诊疗专家组 · 2010-05-01

2011EAU前列腺癌诊疗指南

欧洲泌尿外科学会(EAU,European Association of Urology) · 2011-01-01

前列腺癌诊断标准

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-07-01